Adjuvant chemotherapy for thymic cancer after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of adjuvant chemotherapy in patients with thymic carcinoma who have undergone complete surgical resection. It will compare the outcomes of patients receiving chemoradiotherapy versus those receiving only radiotherapy to determine if the addition of chemotherapy reduces disease progression. Participants will receive a medium dose of a three-drug chemotherapy regimen (paclitaxel, cisplatin, and 5-FU) alongside radiotherapy, with follow-up assessments scheduled every three months for the first two years. The study seeks to clarify the optimal adjuvant treatment approach for this rare cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily participate and sign an informed consent form in writing;
2. Age range from 18 to 75 years old, regardless of gender;
3. Within 3 months after the surgery is completed;
4. Histologically diagnosed with thymic cancer;
5. Complete resection based on surgical records, pathological reports, and postoperative imaging;
6. Masaoka stage: I-III
7. No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency;
8. White blood cells ≥ 3 × 109/L; Neutrophils ≥ 1.5 × 109/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 109/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value;

Exclusion Criteria:

1. Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for more than 3 years after treatment);
2. Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;
3. Pregnancy and lactation period;
4. Patients with drug addiction, chronic alcoholism and AIDS;
5. Researchers believe that participants are not suitable for this experiment.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Xingwen Fa, Doctor
• Email: wenxingfan@126.com
• Phone: +8613651669687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Target-Selected CAR-NK Cells for B2 Thymoma or Thymic Carcinoma

  This study tests whether CAR-NK cells targeting CD30, CD5, or mesothelin can be safely given to adults whose B2 thymoma or thymic carcinoma has come back or not responded to treatment.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07598955

• Sacituzumab Tirumotecan for locally advanced or metastatic thymic carcinoma

  This trial tests whether Sac-TMT can help people with thymic carcinoma after one prior platinum-based therapy.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Shanghai · NCT07324629

• Tislelizumab plus anlotinib as a second-line treatment for thymoma and thymic carcinoma

  This trial will test whether combining tislelizumab with anlotinib is safe and can control thymoma or thymic carcinoma in people whose cancer progressed after first-line chemotherapy (with or without immunotherapy).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06838910

• Using AI to improve diagnosis and recurrence prediction in thymic tumors

  This study is testing if artificial intelligence can help doctors better diagnose thymic tumors and predict the chances of them coming back for patients with these rare cancers.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT06301945

• Testing a new treatment for advanced thymic tumors

  This study is testing a new drug to see if it can help adults with advanced thymic tumors who haven't had success with other treatments.

  Recruiting at 4 sites Phase 2 Georgetown University · Palo Alto, California and 3 other locations · NCT06248515

• Neoadjuvant treatment for advanced thymic cancer

  This study is testing a new treatment that combines a medication with radiation therapy to see if it can help people with advanced thymic cancer have better surgery outcomes.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT06019468

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.